Insider Transactions in Q1 2022 at Fate Therapeutics Inc (FATE)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2022
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.53%
|
$800,000
$32.37 P/Share
|
|
Mar 14
2022
|
Bahram Valamehr Chief R&D Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+10.88%
|
$50,000
$2.73 P/Share
|
|
Mar 10
2022
|
John Mendlein |
SELL
Open market or private sale
|
Direct |
31,562
-8.62%
|
$1,104,670
$35.11 P/Share
|
|
Mar 10
2022
|
John Mendlein |
BUY
Exercise of conversion of derivative security
|
Direct |
31,562
+14.18%
|
$31,562
$1.63 P/Share
|
|
Jan 25
2022
|
Cindy Tahl General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
33,302
+14.97%
|
-
|
|
Jan 25
2022
|
Edward J Dulac Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,302
+19.0%
|
-
|
|
Jan 25
2022
|
Mark Plavsic Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,302
+20.29%
|
-
|
|
Jan 25
2022
|
Yu Waye Chu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,302
+17.68%
|
-
|
|
Jan 25
2022
|
Bahram Valamehr Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,302
+15.62%
|
-
|
|
Jan 21
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.26%
|
$380,000
$38.02 P/Share
|
|
Jan 21
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.21%
|
$20,000
$2.7 P/Share
|
|
Jan 20
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-6.5%
|
$1,200,000
$40.21 P/Share
|
|
Jan 20
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.1%
|
$60,000
$2.73 P/Share
|
|
Jan 11
2022
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,965
-1.58%
|
$190,320
$48.77 P/Share
|
|
Jan 11
2022
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,770
-0.8%
|
$84,960
$48.71 P/Share
|
|
Jan 11
2022
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
4,570
-1.52%
|
$219,360
$48.78 P/Share
|
|
Jan 11
2022
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
5,419
-1.69%
|
$260,112
$48.81 P/Share
|
|
Jan 11
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
14,566
-1.64%
|
$699,168
$48.79 P/Share
|
|
Jan 10
2022
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
5,596
-1.79%
|
$257,416
$46.75 P/Share
|
|
Jan 10
2022
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
7,738
-2.3%
|
$355,948
$46.76 P/Share
|
|
Jan 10
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
34,156
-2.41%
|
$1,605,332
$47.08 P/Share
|
|
Jan 03
2022
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
50,000
-6.12%
|
$2,950,000
$59.19 P/Share
|
|
Jan 03
2022
|
Cindy Tahl General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+18.59%
|
$300,000
$6.55 P/Share
|